Istituto Clinico Humanitas
- Address
- Via Manzoni 56, 20089 Rozzano, Italy
Cardiovascular Diseases and Nephrology Research
At Istituto Clinico Humanitas in Rozzano, clinical trials in cardiovascular disease and kidney disease focus on improving outcomes for people with atherosclerotic cardiovascular disease and chronic kidney disease. The studies are designed to evaluate whether new treatment approaches can better reduce major heart and vascular events.
- Research on atherosclerosis and its impact on long-term cardiovascular risk
- Trials in chronic kidney disease linked to cardiovascular outcomes
- Evaluation of new therapies aimed at preventing major cardiovascular events
These studies support the site’s work in nephrology and dialysis by exploring treatments that may protect both heart and kidney health.
Neoplasms and Breast Cancer Studies
The site also conducts oncology research in neoplasms, with a focus on metastatic breast cancer and estrogen receptor-positive, HER-2 negative advanced breast cancer. This trial activity is centered on testing whether a new treatment strategy can improve disease control compared with current options.
- Studies in advanced breast cancer with detectable ESR1 mutation
- Assessment of treatment effectiveness for metastatic breast cancer
- Research aimed at improving outcomes in hormone receptor-positive cancer
At Istituto Clinico Humanitas, this oncology work reflects a broader effort to refine therapies for difficult-to-treat breast malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eli Lilly & Co.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Istituto Clinico Humanitas
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease | Eli Lilly & Co. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2021-09-30 | 2021-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.